About

Mark Skoda is a serial entrepreneur, health optimization researcher, and founder of MarkSkoda.com — a comprehensive digital platform delivering AI-assisted metabolic health restoration and biological age reversal methodology to individuals seeking alternatives to lifetime pharmaceutical dependency.

Skoda's platform is built on a documented personal transformation that his physicians at Vanderbilt University Medical Center described as unexpected and unprecedented. In July 2025, at age 71, Skoda was fully insulin-dependent following acute idiopathic pancreatitis, weighed 265 pounds, and had been told his Type 2 diabetes was a permanent condition requiring lifetime pharmaceutical management. On his 71st birthday, he initiated a systematic natural intervention protocol built on six integrated pillars: therapeutic intermittent fasting, precision nutrition guided by continuous glucose monitoring, progressive resistance training combined with Zone 2 cardio, evidence-based supplementation, sleep optimization, and behavioral architecture designed to eliminate willpower dependency.

Over the next 150 days, Skoda achieved outcomes that directly challenge the prevailing assumptions of metabolic disease management. His HbA1c dropped from 7.4% to 6.0%, insulin was eliminated entirely, and his biological age was validated at 42 — a 29-year reversal of his chronological age. He recomposed 56 pounds of body mass from 265 to 209 pounds with documented muscle preservation, maintained 95%+ continuous glucose monitor time in target range against a clinical benchmark of 70%, and eliminated multi-decade pharmaceutical dependency representing an estimated $57,000 to $108,000 in avoided five-year costs compared to GLP-1 drug therapy.

Throughout the intervention, Skoda used Claude, an AI developed by Anthropic, as a strategic thinking partner — synthesizing peer-reviewed research, designing multi-variable protocols, interpreting real-time biomarker data, and generating the 57,000-word documentation that formed the basis of his physician review. His endocrinologist described the patient-generated documentation as the most comprehensive ever seen from a patient. The complete case study, prepared to peer-reviewed standards with 80-plus citations, is available in the Research Hub at MarkSkoda.com and is currently being prepared for medical journal submission.

Platform Offerings
MarkSkoda.com launches with a multi-tiered structure designed to make the systematic methodology behind Skoda's transformation accessible at every level of engagement.
The Research Hub is open immediately at no cost to registered members and contains six physician-reviewed documents: the full metabolic reversal case study, an AI-assisted health optimization white paper, a comprehensive supplement protocol, the six-pillar framework overview, a GLP-1 alternative analysis, and a protocol checklist summary.
The Self-Directed Digital Program provides complete protocol documentation, AI methodology guides, and biomarker tracking frameworks for individuals who prefer independent implementation with structured guidance.

The Guided Consulting Program offers direct engagement with Skoda, applying the systematic methodology to individual health profiles. All consulting is designed to complement and coordinate with the client's existing medical team — not replace it.
Speaking and Corporate Wellness Engagements bring Skoda's methodology to keynote audiences at medical conferences, corporate wellness programs, executive health initiatives, and longevity-focused organizations. His story sits at the intersection of entrepreneurial discipline, artificial intelligence, and metabolic science — making it equally relevant to business audiences and health-focused communities.

Market Context
Type 2 diabetes affects an estimated 537 million adults globally, with projections reaching 783 million by 2045. The GLP-1 drug market — led by Ozempic, Wegovy, and Mounjaro — is projected to reach $100 billion annually by 2030, built largely on the premise that metabolic disease requires lifetime pharmaceutical management. Skoda's documented outcomes directly challenge that premise, producing results that GLP-1 drugs do not deliver: genuine metabolic reversal, preserved and increased muscle mass, biological age reduction, and sustainable outcomes without ongoing pharmaceutical dependency.

About Mark Skoda
Mark Skoda brings more than five decades of international business experience across six continents and more than 60 countries to his health optimization work. He has served as CEO of a publicly traded company, led mergers and acquisitions work at UPS, and managed operations involving more than 7,500 direct employees. His current business portfolio includes Neptune FS Global, a water remediation technology company; Iron Gate Records, a music label co-founded with Greg Upchurch of 3 Doors Down; GeoMelody streaming app.